ANGIODYNAMICS, INC. Financials AngioDynamics, Inc.
Equities
ANGO
US03475V1017
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.81 USD | +0.52% |
|
-7.19% | -25.89% |
| Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
| Apr. 05 | Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target | MT |
Valuation
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 699.3 | 384.9 | 881.7 | 761.3 | 371.2 | 232.7 | - | - |
| Enterprise Value (EV) 1 | 699.3 | 384.9 | 881.7 | 761.3 | 371.2 | 232.7 | 232.7 | 232.7 |
| P/E ratio | 11.7 x | -2.34 x | -28.2 x | -28.9 x | -7.11 x | -1.26 x | -6.53 x | -21.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.95 x | 1.46 x | 3.03 x | 2.41 x | 1.1 x | 0.81 x | 0.81 x | 0.74 x |
| EV / Revenue | 1.95 x | 1.46 x | 3.03 x | 2.41 x | 1.1 x | 0.81 x | 0.81 x | 0.74 x |
| EV / EBITDA | 11.4 x | - | 45.2 x | 36.5 x | 16.4 x | -212 x | 22.6 x | 11.5 x |
| EV / FCF | 20,374,298 x | - | - | - | - | - | - | - |
| FCF Yield | 0% | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 37,216 | 37,695 | 38,137 | 38,780 | 39,236 | 40,055 | - | - |
| Reference price 2 | 18.79 | 10.21 | 23.12 | 19.63 | 9.460 | 5.810 | 5.810 | 5.810 |
| Announcement Date | 7/10/19 | 7/16/20 | 7/13/21 | 7/12/22 | 7/12/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 359.5 | 264.2 | 291 | 316.2 | 338.8 | 287.2 | 287.2 | 314.4 |
| EBITDA 1 | 61.46 | - | 19.52 | 20.88 | 22.61 | -1.1 | 10.3 | 20.3 |
| EBIT 1 | 46.31 | 5.635 | 3.174 | 1.241 | 0.111 | -28.88 | -24.12 | - |
| Operating Margin | 12.88% | 2.13% | 1.09% | 0.39% | 0.03% | -10.06% | -8.4% | - |
| Earnings before Tax (EBT) 1 | - | - | -36.05 | -29.95 | -54.44 | -201.7 | -46.44 | -14.4 |
| Net income 1 | 61.34 | -165.8 | -31.55 | -26.55 | -52.44 | -194 | -43.5 | -11.1 |
| Net margin | 17.06% | -62.76% | -10.84% | -8.4% | -15.48% | -67.54% | -15.14% | -3.53% |
| EPS 2 | 1.610 | -4.370 | -0.8200 | -0.6800 | -1.330 | -4.605 | -0.8900 | -0.2700 |
| Free Cash Flow | 34.32 | - | - | - | - | - | - | - |
| FCF margin | 9.55% | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | 55.85% | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 55.95% | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/10/19 | 7/16/20 | 7/13/21 | 7/12/22 | 7/12/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: May | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 78.28 | 73.97 | 87 | 81.54 | 85.43 | 80.71 | 91.07 | 78.68 | 79.07 | 65.97 | 70.9 | 68.82 | 70.96 | 71.09 | 76.4 |
| EBITDA 1 | 4.421 | 6.695 | 6.192 | 2.961 | 7.455 | 4.258 | 7.932 | - | - | -3.647 | -0.9 | 0.3 | 2.1 | 2.3 | 5.6 |
| EBIT 1 | -0.928 | 2.16 | 0.653 | -2.672 | 1.398 | -0.593 | 1.978 | -6.105 | -3.149 | -8.631 | -7.495 | -8.97 | -5.865 | -5.94 | -3.355 |
| Operating Margin | -1.19% | 2.92% | 0.75% | -3.28% | 1.64% | -0.73% | 2.17% | -7.76% | -3.98% | -13.08% | -10.57% | -13.03% | -8.27% | -8.36% | -4.39% |
| Earnings before Tax (EBT) 1 | -8.863 | -5.757 | -6.721 | -13.86 | -9.051 | -9.664 | -21.86 | 34.86 | -12.62 | -202.6 | -14.02 | -13.8 | -11.62 | -11.35 | -7.98 |
| Net income 1 | -8.351 | -4.958 | -6.266 | -13 | -8.486 | -9.485 | -21.47 | 45.88 | -29.05 | -190.5 | -12.88 | -12.66 | -10.72 | -10.4 | -7.43 |
| Net margin | -10.67% | -6.7% | -7.2% | -15.95% | -9.93% | -11.75% | -23.57% | 58.32% | -36.74% | -288.77% | -18.16% | -18.39% | -15.1% | -14.63% | -9.72% |
| EPS 2 | -0.2100 | -0.1300 | -0.1600 | -0.3300 | -0.2100 | -0.2400 | -0.5400 | 1.150 | -0.7200 | -4.730 | -0.2850 | -0.1900 | -0.1500 | -0.1600 | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 1/6/22 | 4/7/22 | 7/12/22 | 10/6/22 | 1/5/23 | 3/30/23 | 7/12/23 | 10/4/23 | 1/5/24 | 4/4/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 34.3 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 5.46% | 0.66% | 0.41% | -0.04% | -0.6% | - | - | - |
| ROA (Net income/ Total Assets) | 4.09% | 0.49% | 0.32% | - | - | - | - | - |
| Assets 1 | 1,498 | -33,533 | -9,843 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 3.12 | 7.59 | 13.7 | 4.3 | 3.81 | - | - | - |
| Capex / Sales | 0.87% | 2.87% | 4.71% | 1.36% | 1.13% | - | - | - |
| Announcement Date | 7/10/19 | 7/16/20 | 7/13/21 | 7/12/22 | 7/12/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.81
USD
Average target price
13.5
USD
Spread / Average Target
+132.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.89% | 233M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.36% | 26.25B | |
| +2.07% | 26.48B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- ANGO Stock
- Financials AngioDynamics, Inc.
